In recent years, cancer research has undergone significant transformation, marked by the introduction of numerous innovative therapies. With the emergence of advanced PD-1/PD-L1 and CTLA-4 immune ...

New York, USA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- LAG-3 Immunotherapies Market Set for Rapid Growth in the Coming 10 Years Across the 7MM as Next-Generation Therapies Advance | DelveInsight The LAG-3 ...

Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levelsDose dependent immunosuppressive ...

LAG-3 is identified as a potential biomarker for SCLC, aiding in patient stratification for ICI therapy. Higher LAG-3 expression in SCLC correlates with improved survival and increased immune activity ...

Australian biotech Immutep has secured $60 million Australian dollars through a “two-tranche institutional placement” as it eyes a deeper push into the clinic and looks to raise a further AU$5 million ...

Bristol Myers Squibb has released a very top-line look at the first late-stage data for a lymphocyte-activation gene 3 (LAG-3) asset, but with no actual figures there’s a lag before we find out just ...

Checkpoint inhibitors are an anticancer drug that indirectly attacks tumors. They depend on infusions of antibodies to block proteins called immune checkpoints. Specifically, they target one of three ...

Immune checkpoint pathways regulate T cell function and play pivotal roles in the treatment of both cancer and autoimmune diseases. One key component of these pathways is Lymphocyte Activation Gene 3 ...

With the recent clinical validation by BMS, LAG-3 combinations are spearheading the next wave of immune checkpoint inhibitors. As such, there has been an explosion of interest and high-scale ...

Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kg The substantial ...